Generic Name and Formulations:
Ibutilide fumarate 0.1mg/mL; soln for IV infusion.
Indications for CORVERT:
Rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm.
Give by IV infusion over 10 minutes. ≥18yrs: (≥60kg) initially 1mg; (<60kg) initially 0.01mg/kg. If no response, may repeat second 10-minute infusion of equal strength given 10 minutes after first infusion. Discontinue infusion as soon as the presenting arrhythmia has terminated, or if sustained/nonsustained ventricular tachycardia or marked QT prolongation occurs.
<18yrs: not recommended.
Risk of fatal arrhythmias (eg, sustained polymorphic ventricular tachycardia, usually associated with QT prolongation (torsades de pointes), but sometimes without documented QT prolongation may occur. Be experienced with the treatment and monitoring of life-threatening arrhythmias before administering. Have cardiac monitoring equipment and proper medication available. Correct hypokalemia and hypomagnesemia before starting. Monitor ECG continuously for at least 4 hours post infusion or until QTC returned to baseline. Proarrhythmia conditions (eg, ventricular arrhythmias, atrial flutter or fibrillation, QTC intervals >440 msec, hypokalemia, history of CHF, low left ventricular ejection fraction). Previous polymorphic ventricular tachycardia: not recommended. Renal or hepatic dysfunction (monitor). Pregnancy (Cat.C). Nursing mothers: not recommended.
Class Ia antiarrhythmics (eg, disopyramide, quinidine, procainamide) or other Class III drugs (eg, amiodarone, sotalol): do not give concomitantly or within 4 hours post-infusion. QT prolongation with phenothiazines, tricyclic and tetracyclic antidepressants, H1 receptor antagonists. Caution with digoxin.
Class III antiarrhythmic.
Ventricular extrasystoles, sustained or nonsustained polymorphic ventricular tachycardia, sustained monomorphic ventricular tachycardia, headache, hypo- or hypertension, tachycardia, bundle branch block, AV block, nausea, QT segment prolonged, bradycardia.
Single-dose vial (10mL)—1
Psychiatry Advisor Articles
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV
- Maintenance rTMS for Treatment-Resistant Depression
- New Study Compares Opioid Dependence Relapse Treatments
- Increase Use of Nursing Home for Patients With Cognitive Impairment Category
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder